Organization · Family Office
The Naissos Group
The Naissos Group is a family-owned private investment firm based in Princeton, NJ, focusing on launching innovative ventures and investing in life sciences companies. Founded in 2008, it manages a diversified portfolio that includes wholly-owned companies and minority investments.
Overview
What The Naissos Group does
What The Naissos Group is
The Naissos Group is a family-owned private investment firm based in Princeton, NJ, focusing on launching innovative ventures and investing in life sciences companies. Founded in 2008, it manages a diversified portfolio that includes wholly-owned companies and minority investments.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Family Office
- Founded
- Founded in 2008
- Approximate age
- About 18 years
- Structured capabilities
- Funder
- Last reviewed
- March 29, 2026
Official channels
Find The Naissos Group elsewhere
Open the official website or a supported primary organization account.
Capability profile
The Naissos Group as a funder
Investment thesis
The Naissos Group focuses on investing in and partnering with innovative companies in the life sciences sector, emphasizing a hands-on approach to management and advisory roles.
Focus narrative
TNG invests primarily in the life sciences sector, targeting companies at various stages, from early-stage biotechs to publicly traded corporations. The firm emphasizes a hands-on approach, actively engaging in the management and advisory roles of its portfolio companies.
Value beyond capital
TNG provides commercial, communications, and clinical operations support to its portfolio companies, actively engaging in management and advisory roles.
Focus and fit
- Stages
- Seed · Series A · Series B · Series C · Series D · Series E · Growth Equity
- Regions
- North AmericaUnited States
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded portfolio count
- 4
Portfolio context
Enterin (2016): A biotech company focused on understanding the gut-brain axis and its role in neurodegenerative diseases. TNG provides commercial, communications, and clinical operations support. Oncolyze (2019): An innovative biotech specializing in oncology therapeutics. TNG has taken an equity position and Alex Stojanovic serves as Chief Operating Officer while TNG Creative acts as the strategic communications agency. Prolocor (2020): Founded by two cardiologists, Prolocor is developing a precision medicine diagnostic for assessing cardiovascular risk. TNG collaborates closely with the company. Avanzarx (2021): A seed-stage biotech focused on developing therapeutics for inflammatory and fibrotic diseases, particularly targeting immunological challenges.
Common questions
What to know about The Naissos Group
Upseed classifies The Naissos Group under the Family Office organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 29, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.